What is the relationship between tofacitinib/Shangjie and methotrexate?

Tofacitinib/Shangjie(Tofacitinib) is a small molecule JAK inhibitor. Its mechanism of action is different from traditional immunosuppressive drugs, but it often forms a therapeutic complementary relationship with methotrexate (MTX) in clinical practice. Methotrexate is the first-line drug for immune diseases such as rheumatoid arthritis (RA) and is considered a "basic therapeutic drug". It can effectively inhibit excessive activation of the immune system and delay joint damage. However, in some patients, methotrexate alone is not effective enough, or the ideal disease control goals cannot be achieved due to adverse reactions. At this time, tofacitinib shows unique advantages.

Tofacitinib inhibits theJanus kinase signaling pathway to reduce the release of inflammatory factors, thereby achieving immune regulation, which is different from the folic acid metabolism antagonism mechanism of methotrexate. Since the two action pathways do not overlap, synergy can be achieved theoretically. Overseas guidelines and clinical practice show that tofacitinib can be used alone or in combination with methotrexate. For patients who have an inadequate response to methotrexate, adding tofacitinib can help improve arthritis symptoms, reduce pain and swelling, and delay bone and joint destruction in the long term.

In addition, combined use can also help reduce the risk of resistance to tofacitinib. Because monotherapy may lose efficacy over time, methotrexate's basic immunomodulatory effects can delay this. It is worth noting that tofacitinib is an oral preparation and is easy to use, while methotrexate is available in oral and injection forms. Doctors will decide whether to use it together based on the patient's specific conditions.

However, you also need to pay attention to safety when using both at the same time. Tofacitinib may cause problems such as increased risk of infection and dyslipidemia, while methotrexate may cause adverse reactions such as liver function damage and oral ulcers. Combination regimens usually require regular monitoring of blood routine, liver and kidney function, and inflammatory indicators to ensure safety.

Reference materials:https://www.xeljanz.com/